The electrification of the transportation sector is crucial for mitigating climate change and has potential co-benefits for public health. This project examines the early phase transition to zero-emission vehicles (ZEVs) in California and its impact on local asthma-related emergency department (ED) visits. Utilizing publicly available datasets from 2013 to 2019, the study analyzes ZEV adoption data, asthma-related ED visit rates, and population characteristics at the zip code level. Descriptive statistics and visualization techniques provide insights into ZEV adoption trends. Linear regression models assess the effects of factors such as registered ZEVs, socioeconomic variables, and calendar year on ED visit rates. Preliminary analysis suggests beneficial respiratory health impacts from reduced air pollution emissions due to the ZEV transition. However, disparities in ZEV adoption among population groups raise concerns about equitable distribution of co-benefits. The study aims to identify communities that could benefit from future policies promoting equitable outcomes. The findings contribute to understanding the health and environmental impacts of ZEV adoption, informing future policy interventions. The project emphasizes addressing inequities in ZEV adoption through effective outreach and accessibility of accurate information. Presentation of findings in a group poster highlights the importance of achieving equitable co-benefits and improving public health outcomes through successful ZEV adoption.

Chronic Myeloid Leukemia (CML) is a type of cancer that begins in the bone marrow and later accumulates in the blood. CML results from an unbalanced translocation where the ABL gene on chromosome 9 is shifted so that it sits next to the BCR gene on chromosome 22 forming what is called the Philadelphia Chromosome. Imatinib – known in the industry as Gleevec – is a successful therapy for CML. It is known that quiescent CML stem cells are resistant to Imatinib, about 25% to 33% of CML patients treated with it will become resistant or intolerant to the treatment. Before Imatinib appeared in the market, Interferon was the standard course of treatment for patients with CML. A particular property of Interferon is that it allows Imatinib to fight leukemic stem cells by breaking their dormancy and driving them to enter the proliferating population. In this work, we are going to analyze the dynamics that exists between CML cells and immune cells under the presence of the combined therapy imatinib-interferon with the assistance of a mathematical model. One of our main objectives is to study the imatinib-interferon combination therapies that could serve to maintain remission on CML patients breaking the resistance of CML to Imatinib treatment.

Bubbles arise in economic situations where the price of a good increases significantly compared to its fundamental value, but they are difficult to study and detect in their formation. The study of bubbles with general equilibrium theory has produced new results, especially Hirano and Toda’s recent 2023 papers on the uniqueness of a rational bubble solution in equilibrium. We use the underlying main theorems in Hirano and Toda (2023) to induce possible bubble conditions in the overlapping generations model (OLG) by changing model parameters computationally to characterize how bubbles would form in any economy.